PT-141, Melanotan I, and Melanotan II are closely related alpha-MSH analogs with overlapping melanocortin receptor activity. They’re not three interchangeable names for the same receptor story, though. Each has its own structure, its own receptor profile, its own research history.
Treating “Melanotan” as one compound with one receptor target flattens a real scientific distinction.
This guide explains how PT-141, Melanotan I, and Melanotan II differ in structure and receptor activity. It also shows how PT-141 is related to Melanotan II, and why approved pharmaceutical products shouldn’t be confused with research-use material.
See Certified Peptide Solutions’ PT-141 and Melanotan research compounds.
What Is PT-141 (Bremelanotide)?
PT-141, also called bremelanotide, is a nonselective melanocortin receptor agonist. It’s pharmacologically active across several receptor subtypes rather than locked onto one. MC1R and MC4R are generally described as the most relevant at typical research exposure levels.
Central-nervous-system research on PT-141 often emphasizes MC4R specifically, part of why the compound gets shorthanded as “the MC4R one” in casual comparisons.
That shorthand undersells its actual receptor profile.
PT-141 has shown up directly in modern structural receptor research too, not just functional assays. In 2021, researchers resolved a high-resolution cryo-electron microscopy structure of bremelanotide bound to full-length MC4R and its Gs signaling complex, visualizing exactly how the compound occupies the MC4R binding pocket.
That makes PT-141 relevant to structural, ligand-binding, and receptor-activation research specifically, not just functional signaling assays.
PT-141 was developed from the Melanotan II scaffold. It’s an extremely close structural analog. Both share the same cyclic seven-residue melanocortin core.
The difference sits at the C-terminus: Melanotan II carries a C-terminal amide, PT-141 carries the corresponding free carboxylic acid at that same position. A precise, documented structural difference. Not a vague “related but different” description.
MC4R itself is heavily studied in energy homeostasis and body-weight regulation research generally.
The receptor sits inside a well-characterized hypothalamic signaling pathway involving POMC and AgRP neurons, a circuit researchers use as a model system for studying how the brain regulates energy balance.
MC4R mutations are among the most well-documented genetic factors studied in monogenic obesity research.
That’s receptor-level biology relevant to PT-141’s research context. Not a description of PT-141’s own defining research application specifically.
What Is Melanotan I (Afamelanotide)?
Melanotan I, also known as afamelanotide or NDP-MSH, is a linear, 13-amino-acid alpha-MSH analog. Its receptor activity sits predominantly at MC1R, though, like the other compounds in this family, it isn’t perfectly receptor-exclusive.
Older receptor-characterization research has found measurable activity at other melanocortin receptor subtypes too.
MC1R is the receptor most closely tied to pigmentation-pathway research. MC1R signaling sits upstream of melanogenesis, the biological pathway that determines the balance between eumelanin and pheomelanin production in skin and hair.
That signaling works predominantly through a Gs-protein-linked cyclic AMP cascade, the same general signaling family used across the melanocortin receptors, though receptor biology involves more than one downstream pathway.
MC1R is also heavily studied in photoprotection and skin-biology research more broadly, including research into MC1R gene variants and UV response.
Melanotan I is more than a historical precursor to an approved pharmaceutical, too.
It remains a widely used melanocortin research reference compound in its own right, showing up in receptor-binding studies, mutagenesis research, and modern structural work on ligand-bound melanocortin receptors.
What Is Melanotan II?
Melanotan II is a cyclic heptapeptide and a broadly nonselective melanocortin receptor agonist, active across MC1R, MC3R, MC4R, and MC5R. It’s a different compound from Melanotan I, structurally and pharmacologically, despite the shared name causing constant confusion between the two.
Where Melanotan I is a linear peptide predominantly active at MC1R, Melanotan II engages a much wider receptor range.
Modern medicinal-chemistry literature still describes Melanotan II specifically as an unselective agonist across the human melanocortin receptors, not an MC1R-focused compound.
That broad receptor activity is exactly why Melanotan II connects directly to PT-141. Both engage MC1R and MC4R, among other subtypes, and PT-141 was developed directly from Melanotan II’s own cyclic scaffold.
When people say “Melanotan” without specifying which one, they usually mean Melanotan II specifically, given how much more that compound circulates in research and commercial discussion.
The two still aren’t pharmacologically interchangeable, though, and shouldn’t be described with the same receptor profile.
Melanotan II also has a well-established role as an experimental reference ligand. A 2024 review of recommended melanocortin receptor research tools identifies MT-II as one of the field’s core synthetic agonists, used in receptor-characterization assays, high-throughput screening, structure-activity research, and functional studies across melanocortin receptor subtypes.
Researchers run into MT-II not just as a compound of independent interest, but as a benchmark newer melanocortin ligands get measured against.
Melanotan II stays relevant to current medicinal chemistry too, not just as a legacy 1990s research compound.
Researchers keep modifying the MT-II structure to study how cyclization, residue substitutions, and conformational changes shift activity across MC1R, MC3R, MC4R, and MC5R, using it as a parent scaffold for building more receptor-selective melanocortin agonists.
How Do PT-141, Melanotan I, and Melanotan II Compare?
PT-141, Melanotan I, and Melanotan II differ across structure, receptor activity, research focus, and regulatory status, summarized side by side below.
| PT-141 (Bremelanotide) | Melanotan I (Afamelanotide) | Melanotan II | |
| Structure | Cyclic heptapeptide | Linear, 13-amino-acid peptide | Cyclic heptapeptide |
| Melanocortin receptor activity | Nonselective; MC1R and MC4R especially relevant | Predominantly MC1R | Broad MC1R/MC3R/MC4R/MC5R agonism |
| Main research emphasis | Central melanocortin signaling, with substantial MC4R-focused research | MC1R, melanogenesis, skin biology | Broad melanocortin pharmacology, including MC1R and central MC3R/MC4R pathways |
| Structural relationship | Very close structural relative of Melanotan II (C-terminal free acid vs. amide) | Distinct linear alpha-MSH analog | Parent scaffold closely related to PT-141 |
| US regulatory status | Active ingredient in an FDA-approved product | Active ingredient in an FDA-approved product | No FDA-approved drug product |
Which Compound Fits Which Melanocortin Research Question?
Which compound fits a given research question comes down to the specific receptor and experimental goal involved, mapped out below.
| Research Question | PT-141 | Melanotan I / NDP-MSH | Melanotan II |
| MC4R structural/signaling research | Strong fit; bremelanotide-MC4R cryo-EM structure available | Studied at MC4R as well | Strong pan-receptor agonist |
| MC1R / melanocyte research | Has MC1R activity, but not the standard reference choice | Strong fit; widely used MC1R reference ligand | Active at MC1R, but nonselective |
| Pan-melanocortin agonist experiments | Relevant, but a distinct profile | Established pan-agonist tool | Widely used reference agonist |
| Receptor-selectivity / SAR studies | Useful comparator | Important reference scaffold | Important cyclic benchmark scaffold |
| High-throughput receptor screening | Possible comparator | Common reference | Common reference agonist |
The practical choice comes down to receptor subtype, assay design, and research endpoint. Not the shared “melanocortin peptide” label.
Regulatory Status Is Separate From Research-Supply Status
Regulatory status and research-supply status are two separate questions for this compound family. Two of the three peptides discussed here are active ingredients in FDA-approved pharmaceutical products.
Bremelanotide is the active ingredient in an FDA-approved prescription product. Afamelanotide, the compound long called Melanotan I, is the active ingredient in a separate FDA-approved product. Melanotan II carries no equivalent approval.
None of that changes the status of research-use material sold under any of these names. A research-use PT-141 or Melanotan product is not the same thing as an approved pharmaceutical product, regardless of shared active-ingredient chemistry.
It should never be described or treated as equivalent to one.
Choosing a Melanocortin Peptide for Research
PT-141, Melanotan I, and Melanotan II are related research compounds. They’re not substitutes for one another, though. PT-141 has been used directly in MC4R structural and signaling research.
Melanotan I, or NDP-MSH, remains a widely used melanocortin reference ligand. Melanotan II functions as a common pan-receptor agonist and medicinal-chemistry scaffold.
The right compound for a given project depends on the receptor subtype, assay design, and research endpoint. Not which name sounds most familiar.
Because those distinctions can come down to small structural changes, exact compound identity and lot-specific analytical documentation matter before selecting material for an experiment.
Sourcing PT-141 and Melanotan for Research
Close structural similarity doesn’t make these peptides analytically interchangeable. PT-141 and Melanotan II share the same cyclic scaffold and differ at one specific position: the C-terminus, amide versus free acid.
A chromatographic purity percentage alone can’t tell you which of the two is actually in a given vial. A listing that just says “Melanotan” without specifying Melanotan I or Melanotan II leaves an even bigger identity question wide open, given how differently the two behave pharmacologically.
For synthetic peptides, identity and chromatographic purity answer two different questions. FDA peptide-quality research has used high-resolution liquid chromatography and mass-spectrometry methods to establish peptide identity and characterize low-level peptide-related impurities, noting that synthetic peptide impurities can arise from incomplete coupling, truncation, side reactions, and other synthesis-related processes.
FDA guidance on synthetic peptides specifically recommends sensitive, high-resolution analytical methods for catching these impurities. For a research buyer, that makes identity-specific analytical documentation matter just as much as a reported purity percentage.
That comes down to the same documentation standards that apply across any research peptide: a batch-specific certificate of analysis, identity testing appropriate to the specific compound, and chromatographic purity data tied to the exact lot in hand.
Certified Peptide Solutions’ guide to reading a peptide certificate of analysis covers how to evaluate that documentation for any research peptide, PT-141 and Melanotan included.
Frequently Asked Questions
What is PT-141 (bremelanotide)?
PT-141, or bremelanotide, is a synthetic cyclic peptide that acts as a nonselective melanocortin receptor agonist. PT-141 is active at several melanocortin receptor subtypes, with much of the central nervous system research focusing on MC4R. It was structurally developed from Melanotan II.
What is Melanotan?
Melanotan can refer to two different compounds, Melanotan I and Melanotan II. Melanotan I, or afamelanotide, is a linear peptide with activity centered mainly on MC1R. Melanotan II is a cyclic peptide with broader activity across MC1R, MC3R, MC4R, and MC5R.
How do PT-141 and Melanotan differ in receptor target?
PT-141 and Melanotan II have overlapping activity at several melanocortin receptors, including MC1R and MC4R. Melanotan I is much more strongly associated with MC1R activity. PT-141, Melanotan I, and Melanotan II therefore shouldn’t be described as three compounds acting through the same receptor profile.
What is the difference between Melanotan I and Melanotan II?
Melanotan I and Melanotan II differ in both structure and receptor activity. Melanotan I is a linear 13-amino-acid peptide primarily associated with MC1R. Melanotan II is a cyclic heptapeptide with broader activity across MC1R, MC3R, MC4R, and MC5R. PT-141 was developed structurally from Melanotan II.
Are PT-141 and Melanotan the same compound?
No. PT-141, Melanotan I, and Melanotan II are distinct compounds. PT-141 and Melanotan II are close structural relatives that share the same cyclic scaffold, while Melanotan I is a separate linear peptide. PT-141 and Melanotan II also differ at the C-terminus.
Are PT-141 or Melanotan FDA-approved?
Bremelanotide and afamelanotide are active ingredients in FDA-approved pharmaceutical products, while Melanotan II doesn’t have equivalent FDA approval. That approval belongs to the specific finished drug products FDA reviewed and doesn’t extend to research-use materials sold under the PT-141, bremelanotide, afamelanotide, or Melanotan names.
For laboratory research only. Not for human or veterinary use. Not for human consumption. No therapeutic, diagnostic, dosing, or treatment claims are made. See Certified Peptide Solutions’ Research Purposes Only policy for full research-use guidance.